{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product, was also an adverse event. The number of participants that discontinued study treatment due to an AE was reported per protocol for the first course of treatment.","groups":[{"description":"Participants receive pembrolizumab 200 mg IV Q3W for up to 35 treatments (approximately 2 years).","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All allocated participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 24 months","title":"Number of Participants That Discontinued Study Treatment Due to an AE","type":"SECONDARY","unitOfMeasure":"Participants"}